Group | No. | Age (y) | Initial pathology | Surgical type | Recurrent pathology | Postoperative pathology | Myometrial infiltration | Pathology before and after surgery | Postoperative management | Prognosis | Follow-up time(m) |
Without retreatment | 1 | 40 | AEH | TH | AEH | No lesions | – | Consistent | – | NED | 9 |
2 | 36 | AEH | TH | AEH | AEH | – | Consistent | – | NED | 30 | |
3 | 37 | AEH | TH | AEH | EC IaG1 | – | Upgradea | – | NED | 11 | |
4 | 32 | AEH | Staging surgery | EC IaG1 | EC IaG1 Ovarian inclusion cyst (right ovary) | Superficial | Consistent | – | NED | 9 | |
5 | 24 | EC Ia G1 | TH | EC IaG1 | EC IaG1 | Superficial | Consistent | – | NED | 53 | |
6 | 28 | EC IaG1 | TH | EC IaG1 | EC IaG1 | Superficial | Consistent | – | NED | 25 | |
7 | 32 | AEH | Staging surgery | EC IaG1 | EC IaG1 | Superficial | Consistent | – | NED | 3 | |
Failure to retreatment | 8 | 28 | AEH | TH | AEH | AEH | – | Consistent | – | NED | 70 |
9 | 34 | AEH | Staging surgery | EC IaG1 | EC IaG1; ovarian endometrioid adenocarcinoma IC2 (left ovary) | Superficial | Consistent | Four courses of chemotherapy | NED | 5b | |
10 | 28 | EC IaG1 | TH+BSO(preserving partial left ovary) | EC IaG1 | EC IaG1; ovarian borderline endometrioid adenocarcinoma (bilateral ovaries) | – | Consistent | – | NED | 22 | |
11 | 33 | EC IaG1 | TH | AEH | EC IaG1 | Superficial | Upgradea | – | NED | 118 | |
Fertility completed | 12 | 28 | EC IaG1 | (CR)subtotal hysterectomy | EC IaG1 | No lesions | – | Consistent | – | NED | 3 |
Multiple recurrence | 13 | 34 | AEH | Staging surgery | EC IaG1 | EC IIIc G1 | – | Upgradea | Six courses of chemotherapy | NED | 5b |
14 | 33 | EC IaG1 | Staging surgery (preserving bilateral ovaries) | EC IaG1 | EC IaG1 | – | Accord | – | NED | 26 | |
15 | 36 | AEH | TH | EC IaG2 | EC Ia | – | Accord | – | NED | 61 |
TH, total hysterectomy; BSO: bilateral salpingooophoreclomy; EC, endometrial cancer; AEH, atypical endometrial hyperplasia; NED: no evidence of disease.
↵a Upgrade: pathological type upgrades (AEH before while EC after), or pathological stage upgrades.
↵b Follow-up time: duration between last course of chemotherapy and the last follow-up.